Journals / Southern Clinics of Istanbul Eurasia / 2021 / Cilt: 32 - Sayı: 3

Neutrophil-to-lymphocyte Ratio as a Predictor of Prognosis in Patients with Small Cell Lung Cancer: A Retrospective Study

Pages
260–267
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median overall survival (OS) was worse in the high-NLR group than in the low-NLR group (Group 1).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Neutrophil-to-lymphocyte Ratio (NLR) is an easily measurable parameter with prognostic value for various types of cancer.
📊
Key Findings & Data:Methods: A retrospective cohort study enrolled 396 patients diagnosed with SCLC between January 1, 2008, and December 31, 2012 in the department of chest diseases of a tertiary hospital.
💡
Conclusion & Impact:Median overall survival (OS) was worse in the high-NLR group than in the low-NLR group (Group 1).
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Neutrophil-to-lymphocyte Ratio (NLR) is an easily measurable parameter with prognostic value for various types of cancer. The role of NLR in terms of prognosis in small cell lung cancer (SCLC) is controversial. The aim of this study was to investigate the relationship between NLR, platelet-to-lymphocyte ratio (PLR), other potential factors and prognosis in patients with SCLC. Methods: A retrospective cohort study enrolled 396 patients diagnosed with SCLC between January 1, 2008, and December 31, 2012 in the department of chest diseases of a tertiary hospital. Patients were grouped according to their NLR levels at the time of diagnosis; low-NLR (<4) (Group 1) and high-NLR (≥4) (Group 2). These groups were compared with the recorded data and predictors of mortality and the results were analyzed. Results: Patients with low-NLR (<4) (Group 1) had worse performance status, extensive stage, and lower response rate compared to patients with high-NLR (≥4) (Group 2). Median overall survival (OS) was worse in the high-NLR group than in the low-NLR group (Group 1). In contrast, elevated PLR was not associated with OS. Multivariate analysis showed that elevated NLR and lactate dehydrogenase, stage, smoking history, presence of malign pleural effusion were independent prognostic factors for OS. Conclusion: Elevated NLR is easily measurable can be used as a prognostic marker that reflects poor prognosis, while PLR is not associated with survival for patients with SCLC.

🔖

Cite This Article

GÜNEY, P. A., IRMAK, I., KASAPOĞLU, U. S., ARINÇ, S. (2021). Neutrophil-to-lymphocyte Ratio as a Predictor of Prognosis in Patients with Small Cell Lung Cancer: A Retrospective Study. Southern Clinics of Istanbul Eurasia, Cilt: 32 - Sayı: 3, 260–267. https://ajindex.com/articles/415184

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Buccheri G, Ferrigno D. Prognostic factors of small cell lung cancer. Hematol Oncol Clin North Am 2004;18:445–60
  2. Kort S, Brusse-Keizer M, Schouwink H, De Jongh F, Citgez E, Gerritsen J, et al. Detection of small cell lung cancer by electronic nose. International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies. p. 1762
  3. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20–37
  4. Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S; Norweigian Lung Cancer Study Group. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003;39:303–13
  5. Yoshino I, Maehara Y. Impact of smoking status on the biological behavior of lung cancer. Surg Today 2007;37:725–34
  6. Greenberg AK and Lee MS: Biomarkers for lung cancer: Clinical uses. Curr Opin Pulm Med 2007;13:249–55
  7. Yu Y, Qian L, Cui J. Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients. Mol Clin Oncol 2017;7:498–506
  8. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009;16:614–22
  9. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 2010;16:219–23
  10. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011;54:948–55
  11. Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: Linking proinflammatory responses to procoagulant state. Thromb Res 2013;131:191–7
  12. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17:216–22
  13. Gu X, Sun S, Gao XS, Xiong W, Qin S, Qi X, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep 2016;6:23893
  14. Bardash Y, Olson C, Herman W, Khaymovich J, Costantino P, Tham T. Platelet-lymph